Phoenix Molecular Designs Initiates its Phase 1/1b Program to Evaluate PMD-026 in Patients with Resistant Forms of Advanced Breast Cancer

Nov. 20
2019

SAN DIEGO and VANCOUVER, British Columbia, Nov. 20, 2019 - PhoenixMD announced today that it has dosed the first patient in its Phase 1/1b study of PMD-026, a proprietary first-in-class orally-available RSK (kinase) inhibitor for the potential treatment of patients with metastatic breast cancer and, more specifically, triple-negative breast cancer (TNBC).

Read the story here